RADVAX FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A PHASE II TRIAL OF PEMBROLIZUMAB + LOW DOSE RADIOTHERAPY
Brief description of study
This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is not currently approved for most non-Hodgkin lymphomas. Your physicians will monitor your cancer’s response to these treatments as well as any side effects you may experience.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
non Hodgkin lymphoma,
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 844686
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
